New
On March 21, 2024, French health authorities granted special permission for doctors to prescribe Protopic 0.1% (Tacrolimus) for treating vitiligo in adults and children over 2 years old. This kind of permission is given when there's already a different approved treatment available, but this ointment might better meet some patients' needs.
Companies Pierre Fabre Médicament and Léo Pharma A/S that make this ointment must follow certain rules for using it and keeping track of how it's working. This includes regular updates to a health monitoring center in Toulouse and providing summaries of how the treatment is going.
This special permission is set for three years from the day after the decision was announced on the ANSM website. The director general of the health authority, Christelle Ratignier-Carbonneil, signed off on this decision.
FAQOther Questions
- How can I cure vitiligo?
Currently, there is no cure for vitiligo. However, many treatments can help manage the condition by restoring skin pigmentation, halting the progression of depigmentation, and i...
- Does vitiligo increase the risk of skin cancer?
No, it does not. Despite common misconceptions, people with vitiligo are actually at a lower risk of developing skin cancer—including both nonmelanoma skin cancer (NMSC) and mal...
- What is vitiligo?
Vitiligo (pronounced vit-ill-EYE-go) is a generally unpredictable skin disease that causes a gradual loss of skin color and overlying hair on different parts of the body. Cont...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.